Cipla share price gains on launching rapid antigen detection test
The company will commence the supply of rapid antigen test kits for COVID-19 in India from this week.
Shilpa Medicare can make 100-200 million doses of COVID-19 shot, says executive
Cipla share price gained in the early trade on December 16 after the company announced its partnership with the Premier Medical Corporation for commercialisation of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week.
This is Cipla's second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit.
In this collaboration, Cipla will be responsible for the marketing and distribution of the rapid antigen detection test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Private Limited.
The test is a rapid point-of-care nasopharyngeal swab test that directly detects the presence or absence of coronavirus antigen in the patient's body, generating results within 15-20 minutes.
